Drug Trial Radar · NCT04755543
A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms
Last checked: Nov 19, 2026Latest source record: Feb 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
94
Planned (sponsor's estimate)
Start
Jun 17, 2019
Primary completion
Jun 30, 2021
Study completion Jun 30, 2022
Sponsor
- Lead sponsor
- Taizhou HoudeAoke Biomedical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 16, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
LP002 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors. In this study, the safety, pharmacokinetics and preliminary efficacy of LP002 for the treatment of malignant digestive system neoplasms will be evaluated.
Conditions
- Digestive System Neoplasms
Interventions
LP002Drug
600mg or 900 mg by intravenous (IV) infusion on Day 1, every 2 weeks (Q2W).
CisplatinDrug
50mg/m2 IV on Day 1, Q2W
FluorouracilDrug
2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W
OH2 oncolytic virusBiological
106 or 107 or 108 CCID50/mL by intra-tumoral injection, Q2W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0Time frame: up to approximately 24 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Henan Cancer Hospital & Insititute
Zhengzhou, Henan, China · Recruiting
Hubei Cancer Hospital & Insititute
Wuhan, Hubei, China · Recruiting
Liaoning Cancer Hospital & Insititute
Shenyang, Liaoning, China · Recruiting
The First Affiliated Hospital. Zhejiang University School Of Medicine
Hangzhou, Zhejiang, China · Recruiting
The First Affiliated Hospital. Zhejiang University School Of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.